EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Evidence-Based Medicine 2006;11:173; doi:10.1136/ebm.11.6.173
Copyright © 2006 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thien, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thien, F.
Topic Collections
Right arrowRelevant Article

Therapeutics

Sublingual immunotherapy with a grass allergen tablet improved symptoms and quality of life in allergic rhinoconjunctivitis

Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802–9.[CrossRef][Medline]

Q In patients with grass pollen-induced allergic rhinoconjunctivitis, how effective is sublingual immunotherapy with a grass allergen tablet?

Clinical impact ratings GP/FP/Primary care *****{star}{star} Allergy & immunology ******{star}

Key Words: allergens • conjunctivitis (allergic) • desensitisation (immunologic) • Poaceae • rhinitis (allergic, seasonal)

The first 150 words of the full text of this article appear below.

METHODS
Formula Design: randomised placebo controlled trial.

Formula Allocation: unclear allocation concealment.*

Formula Blinding: blinded (patients, healthcare providers, and outcome assessors).*

Formula Follow up period: up to the end of grass pollen season.

Formula Setting: 55 centres in Canada, UK, Germany, Belgium, Austria, Denmark, Sweden, and Norway.

Formula Patients: 855 patients 18–65 years of age (mean age 35 y, 62% men) who had allergic rhinoconjunctivitis during grass pollen season for >=2 years and positive result on skin prick test to timothy grass (Phleum pratense). Exclusion criteria included history of asthma, anaphylaxis, or angio-oedema; forced expiratory volume1 <70% predicted; non-grass induced allergic rhinitis; recurrent acute or chronic sinusitis; conjunctivitis, rhinitis, or asthma at randomisation; hypersensitivity to trial medication; and immunotherapy for allergens in the past 5–10 years.

Formula Intervention: oral P pratense pollen tablets (GRAZAX, ALK-Abelló, Denmark), 0.5 µg pollen with rescue medication (RM) (n = 136), 5 µg pollen with RM (n = 139), 15 µg . . . [Full text of this article]

Frank Thien, MD, FRACP

Alfred Hospital and Monash University,
Melbourne, Victoria, Australia


Relevant Article

Glossary
Evid. Based Med. 2006 11: 191. (in Glossary) [Extract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.